Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellectis SA

www.cellectis.com

Latest From Cellectis SA

Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen

Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.

Deals M & A

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Deals Business Strategies

Servier To Tackle Parkinson's With Oncodesign Pact

A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.

Neurology Deals

AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

 

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
        • Natural Products
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Cellectis SA
  • Senior Management
  • Andre Choulika, PhD, CEO
    Eric Dutang, CFO
    Elsy Boglioli, COO
    Philippe Duchateau, PhD, CSO
    Stephane Depil, MD, PhD, SVP, R&D & CMO
  • Contact Info
  • Cellectis SA
    Phone: (33) 81 69 16 00
    8 rue de la Croix Jarry
    Paris, 93235
    France
UsernamePublicRestriction

Register